MX2009000659A - Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. - Google Patents

Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.

Info

Publication number
MX2009000659A
MX2009000659A MX2009000659A MX2009000659A MX2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A
Authority
MX
Mexico
Prior art keywords
methods
present
herv
immune response
immunogenic compositions
Prior art date
Application number
MX2009000659A
Other languages
English (en)
Spanish (es)
Inventor
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Ashish Agrawal
Jack Lenz
Frederick M Hecht
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2009000659A publication Critical patent/MX2009000659A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2009000659A 2006-07-21 2007-07-19 Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. MX2009000659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21
PCT/US2007/016403 WO2008011120A2 (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009000659A true MX2009000659A (es) 2009-06-08

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000659A MX2009000659A (es) 2006-07-21 2007-07-19 Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.

Country Status (15)

Country Link
US (2) US20080171061A1 (enExample)
EP (1) EP2046380A4 (enExample)
JP (1) JP2009544614A (enExample)
KR (1) KR20090060410A (enExample)
CN (1) CN101557823A (enExample)
AU (1) AU2007275693A1 (enExample)
BR (1) BRPI0714714A2 (enExample)
CA (1) CA2658393A1 (enExample)
IL (1) IL196516A0 (enExample)
MX (1) MX2009000659A (enExample)
NO (1) NO20090818L (enExample)
RU (1) RU2009106089A (enExample)
SG (1) SG173997A1 (enExample)
WO (1) WO2008011120A2 (enExample)
ZA (1) ZA200900379B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2340851A4 (en) * 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
EP2519539A4 (en) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US20160145348A1 (en) 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP7046016B2 (ja) 2016-06-30 2022-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法
WO2018037042A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
WO2018129270A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
EP3606550A2 (en) * 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
WO2020049169A1 (en) * 2018-09-06 2020-03-12 Centre Léon-Bérard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
WO2024108001A2 (en) * 2022-11-16 2024-05-23 The General Hospital Corporation Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules
US20260035415A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20030162263A1 (en) * 2001-09-06 2003-08-28 Marc Dupuis Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
JP4822490B2 (ja) * 2001-12-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
US20130108653A1 (en) * 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
WO2008011120A2 (en) 2008-01-24
US20080171061A1 (en) 2008-07-17
CA2658393A1 (en) 2008-01-24
RU2009106089A (ru) 2010-08-27
EP2046380A4 (en) 2013-05-01
BRPI0714714A2 (pt) 2013-04-09
CN101557823A (zh) 2009-10-14
IL196516A0 (en) 2011-08-01
AU2007275693A1 (en) 2008-01-24
SG173997A1 (en) 2011-09-29
ZA200900379B (en) 2010-08-25
KR20090060410A (ko) 2009-06-12
JP2009544614A (ja) 2009-12-17
US20130323279A1 (en) 2013-12-05
NO20090818L (no) 2009-04-17
EP2046380A2 (en) 2009-04-15
WO2008011120A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2008011120A3 (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2009038756A3 (en) Long interspersed nuclear element polypeptide compositions and methods of use thereof
PH12012502272A1 (en) Biological materials related to her3
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
EP2470559A4 (en) COZY FACTORY IX COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
WO2006103666A3 (en) Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
UA107921C2 (xx) Варіанти поліпептидів рецептора іів активіну та їх використання
WO2010115998A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2006089001A3 (en) Lentiviral vectors and their use
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
TN2012000393A1 (en) Agonist dr5 binding polypeptides
MY156286A (en) Human il-23 antigen binding proteins
IN2012DN02981A (enExample)
MY177065A (en) 4-1bb binding molecules
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
MX2013008375A (es) Anticuerpos anti proteina accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
NZ706884A (en) Fc gamma receptor iib variants
MX2010009071A (es) Peptidos aislados que tienen actividad inhibitoria de fosfolipasa.
MX2009007261A (es) Vacuna de peptido foxp3.
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom

Legal Events

Date Code Title Description
FA Abandonment or withdrawal